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Abstract
Psoriatic arthritis (PsA) is an immune-mediated, clinically heterogeneous disease characterized by arthritis, enthesitis,
dactylitis, spondylitis, and psoriasis of the skin and nails. Persistent articular inflammation in patients with PsA can
lead to structural damage, which can result in reduced physical function and quality of life. Structural damage can
occur rapidly, and irreversible joint damage may be observed if patients are not treated promptly and appropriately.
Therefore, evaluating therapeutic agents for their ability to inhibit structural progression has become increasingly
important, with radiographic progression becoming a key efficacy outcome in clinical trials in PsA. Here, we review
how structural damage and progression are assessed in clinical trials and the use of radiographic progression as a
study outcome. We also discuss possible limitations in the current assessment of radiographic progression as well
as areas of research that may improve the assessment of structural damage in clinical trials of PsA.
Keywords: Psoriatic arthritis, Structural damage, PsA radiographic scoring systems, Biologic agents, Peripheral
arthritis
Background
Psoriatic arthritis (PsA) is an inflammatory disease that
develops in approximately 25% of patients with psoriasis
[1] and is characterized by arthritis, enthesitis, dactylitis,
spondylitis, and psoriasis of the skin and nails [2]. Per-
sistent inflammation can damage patients’ cartilage and
bone, leading to bony erosions and joint space narrow-
ing or total joint destruction; in addition, some patients
experience abnormal new bone growth [3, 4].
PsA was initially considered a mild disease, but evi-
dence has shown that PsA has a substantial impact on
patient quality of life and disability [5]. This is largely
due to the structural damage associated with the disease,
with a higher degree of joint damage correlating with
greater disability and limitation of physical function [6].
Structural damage of joints is typically measured with
conventional radiographs, and almost half of patients ex-
hibit structural damage and functional impairment
within 2 years of developing symptoms [7]. Many
experience irreversible joint damage and disability as the
disease progresses [7], and a diagnostic delay of > 6
months between symptom onset and the first rheuma-
tologist visit has been linked to the development of per-
ipheral joint erosions and worse long-term physical
function [8]. In addition, radiographic damage has been
found to be prognostic of shorter survival in patients
with PsA [9].
Given the impact of joint damage on physical function,
quality of life, and survival, inhibiting progression of
structural damage is one of the main goals of therapy
[10, 11]. Therefore, assessment of structural damage
progression has become important in clinical trials
evaluating treatments for PsA. Radiographic progression
is currently the preferred outcome measure for struc-
tural damage progression, with therapeutic agents that
inhibit radiographic progression considered to be disease
modifying [10, 11]. This article reviews the various scor-
ing systems used to assess radiographic damage in the
peripheral joints of patients with PsA, as well as the use
of structural damage as an outcome measure in clinical
trials.
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Methods
Relevant articles were identified by conducting a tar-
geted search of the medical literature available in
PubMed. A broad search was initially performed using
psoriatic arthritis in combination with various terms, in-
cluding radiographic progression, scoring method, struc-
tural damage, radiography, and clinical trial. Identified
articles were considered relevant if they presented data
on the imaging and scoring of structural damage in
psoriatic arthritis and the use of radiographic progres-
sion as an outcome measure in clinical trials. Additional
articles were identified from the references cited in arti-
cles of interest and based on the authors’ knowledge of
the published literature.
Assessing structural damage in PsA
Imaging techniques
Radiographs have been used to measure the extent of
damage in clinical trials of PsA over the last 20 years and
remain the standard approach for assessment of struc-
tural damage [3, 12]. Radiographs are used to determine
the presence of periostitis (which has a “fluffy” charac-
teristic in PsA), assess joint damage (e.g., bone erosions,
osteolysis, subluxation, ankylosis), determine involve-
ment of the sacroiliac joint and joints of the spine, and
identify spurs at the entheses [3, 12].
Newer imaging modalities, including ultrasound, mag-
netic resonance imaging (MRI), and high-resolution
micro-computed tomography, have recently been used
to assess structural damage progression in PsA. How-
ever, these techniques are not frequently used to evalu-
ate outcomes in clinical trials and will therefore not be
discussed in this review.
Current radiographic scoring methods for structural
damage progression in PsA
Several semiquantitative scoring systems (Table 1) have
been developed for the assessment of structural damage
progression in PsA. Although they may be of limited use
in the clinic, these scoring methods have proven very
important in clinical research and have been used in
many clinical trials to assess radiographic progression in
the peripheral joints of patients with PsA (Table 2).
These methods were originally developed for use in
rheumatoid arthritis [3, 4] but have been modified for
use in PsA [3], and some have been used in trials of bio-
logic or targeted synthetic disease-modifying antirheu-
matic drugs [15, 17, 19–23, 25–27, 29, 30, 32]. The
original scoring methods in rheumatoid arthritis in-
volved assigning scores for bony erosions and joint space
narrowing in various combinations of joints in the
hands, wrists, and feet. Modifications to the scoring
methods for use in PsA included adding joints involved
more frequently in PsA and signs that are characteristic
of PsA, such as the pencil-in-cup change, gross osteoly-
sis, and ankylosis (Table 1) [3].
Modified Steinbrocker global scoring method
The original Steinbrocker method classified patients
with rheumatoid arthritis according to functional and
radiographic damage and assigned each patient a score
of 0 (normal) to 4 (total joint destruction) based on
the patient’s worst joint [3, 12]. The University of To-
ronto Psoriatic Arthritis Clinic modified the method
for use in PsA to include 42 joints in the hands, wrists,
and feet and assigned each joint a single score from 0
to 4 to reflect the extent of both erosion and joint
space narrowing, for a total score ranging from 0 to
168 (Table 1) [12, 13].
Sharp scoring method for PsA
The PsA-modified Sharp method typically assesses joints
of the hands, wrists, and feet, including the second to
fifth distal interphalangeal (DIP) joints of both hands
(total score range, 0–470); a separate evaluation of ero-
sions and joint space narrowing is also performed (Table
1) [3, 4]. Erosion is measured on a scale of 0 to 5 (total
range, 0–270) and accounts for both the number of
discrete erosions and percentage of joint involvement,
with 0 defined as no erosion and 5 defined as extensive
destruction involving > 80% of the joint. Extreme bone
destruction (pencil-in-cup changes, gross osteolysis) may
also be captured separately, but these are not included
in the total erosion score. Joint space narrowing is
scored on a scale of 0 to 4 (total range, 0–200), with a
normal joint assigned a score of 0 and the absence of
joint space or evidence of ankylosis a score of 4. Joint
space widening is scored separately; however, it is not
included in the total joint space narrowing score. Simi-
larly, other PsA-associated structural damages (e.g., peri-
ostitis, tuft resorption) are recorded separately, but are
also not included in the total score value.
Sharp-van der Heijde scoring method for PsA
The Sharp-van der Heijde score modified for PsA (SvdH;
total score range, 0–528) also assesses joints of the
hands, wrists, and feet and includes DIP joints 2 to 5 of
both hands (Table 1) [3, 4]. Scores for erosion range
from 0 to 5 in the hands and 0 to 10 in the feet and re-
flect erosion size, with 0 defined as no erosion and 3 de-
fined as a large erosion passing the midline of the joint.
If there is > 1 erosion per joint, scores can be combined
to give a maximum score of 5 per joint in the hands and
10 per joint in the feet (a maximum of 5 at each side of
the joint). Joint space narrowing scores vary from 0 to 4
in both the hands and feet, with 0 being normal and 4
being the absence of joint space with evident ankylosis
or subluxation [3, 4]. Gross osteolysis and pencil-in-cup
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change are scored separately and, if present, are assigned
the maximum score for erosion and joint space narrow-
ing for the same affected joint [3].
Psoriatic Arthritis Ratingen score
The Psoriatic Arthritis Ratingen score (PARS) is the only
scoring system that was specifically designed for PsA
and may better account for the bone pathology changes
(destruction and proliferation) seen in these patients [3,
4, 14]. Destruction is scored from 0 to 5 and measures
percentage of joint surface destruction, with a score of 5
reflecting destruction of > 75% of the joint surface (Table
1). Proliferation is scored from 0 to 4 and measures bony
outgrowth in millimeters, also accounting for the size of
the new growth relative to the original diameter of the
bone [3, 4]. The PARS score includes assessment of 30
joints in the hands and 10 joints in the feet, with a po-
tential proliferation score of 0 to 200 and destruction
score of 0 to 160, yielding a total score ranging from 0
to 360 [3, 4].
Comparison of scoring methods
Although all four methods (the modified Steinbrocker
scoring method, the modified Sharp score, the SvdH
method, and the PARS) are reliable in the assessment
of radiographic progression, no direct comparison of
their performance in clinical trials has been conducted.
The modified Steinbrocker scoring method is generally
easier to learn and use but is less sensitive than
methods based on the modified Sharp score; this lower
Table 1 Comparison of radiographic progression scoring methods in psoriatic arthritis trials
Scoring
method
Total joints, n
(range of score)
Locations
(total joints, n)
Damage score per joint Additional
features
recorded
Modified
Steinbrocker
[12, 13]
42 (0–168) Hands (28)
Wrists (2)
Feet (12)
0 = normal
1 = soft tissue swelling/osteopenia
2 = erosion
3 = erosion plus JSN
4 = total joint destruction
–
Typical
modified
Sharp used
for PsA [4]
Erosion, 54;
JSN, 50 (erosion,
0–270; JSN, 0–200;
total, 0–470)
Hands (28)
Wrists
(erosion, 14;
JSN, 12)
Feet (erosion,
12; JSN, 10)
Erosion:
0 = no erosion
1 = 1 discrete erosion or < 21% of
joint
2 = 2 erosions or 21–40% of joint
3 = 3 erosions or 41–60% of joint
4 = 4 erosions or 61–80% of joint
5 = extensive destruction, > 80%
of joint
JSN:
0 = normal joint
1 = asymmetrical/minimal
narrowing
2 = definite narrowing with
loss of ≤ 50%
3 = definite narrowing with
loss of 51–99%
4 = absence of joint space, ankylosis
Pencil
in cup;
joint
space
widening
Sharp-van der
Heijde for
PsA [4]
52 (erosion, 0–320;
JSN, 0–208; total,
0–528)
Hands (28)
Wrists (12)
Feet (12)
Erosion:
0 = no erosions
1 = discrete erosion
2 = large erosion not passing
midline
3 = large erosion passing midline
Scores can be combined if > 1
erosion per joint is present for a
maximum score of 5 per joint in
the hands and 10 per joint in the
feet
[Score of 5/10 if pencil-in-cup
change or gross osteolysis
present]
JSN:
0 = normal joint
1 = asymmetrical/minimal narrowing up to 25%
2 = definite narrowing with
loss ≤ 50%
3 = definite narrowing with loss
of 51–99% or subluxation
4 = absence of joint space, ankylosis,
or complete luxation
[Score of 4 if pencil-in-cup change or
gross osteolysis present]
Pencil
in cup;
gross
osteolysis
Psoriatic
Arthritis
Ratingen
Score [14]
40 (destruction,
0–200; proliferation,
0–160; total, 0–360)
Hands (28)
Wrists (2)
Feet (10)
Destruction:
0 = normal
1 = ≥ 1 erosion, > 1 mm
interruption of cortical plate, with
up to 10% destruction of joint
surface
2 = 11–25% destruction of joint
surface
3 = 26–50% destruction of joint
surface
4 = 51–75% destruction of joint
surface
5 = > 75% joint surface
destruction
Proliferation:
0 = normal
1 = bony proliferation of 1–2 mm or bone
growth < 25% of original diameter
2 = bony proliferation 2–3 mm or bone growth
of 25–50%
3 = bony proliferation > 3mm or bone growth
of > 50%
4 = bony ankylosis
–
JSN joint space narrowing, PsA psoriatic arthritis
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level of sensitivity may be one reason the modified
Steinbrocker method has not been routinely used in
clinical trials [33]. The SvdH method for PsA has been
used to evaluate treatment in several studies of biologic
agents and has shown good sensitivity and reliability
(Table 2) [19–30, 32, 34].
A study by Tillet and colleagues compared the four
scoring methods to assess their utility in PsA [33]. Ra-
diographs of hands and feet from 50 patients with PsA
were scored at two time points by two readers using
each of the four methods. Sensitivity to change was esti-
mated using a standardized response mean and smallest
Table 2 Assessment of radiographic progression in psoriatic arthritis trials
Study Scoring
method
Radiographic
assessment
time point,
week
Mean change in radiographic score at
week 24
Proportion of patients with no progression (mean
change ≤ 0.5) at week 24, %
Placebo Active treatment Placebo Active treatment
Etanercept vs
placebo
(phase 3) [15, 16]
Sharp 24 and 48 1.0a − 0.03a 8.6a,b 33.8a,b
ADEPT (adalimumab
vs placebo) [17, 18]
Sharp 24 1.0 − 0.2 71.1 91.0
IMPACT (infliximab
vs placebo) [19]
SvdH 50 − 1.95 (PBO/
infliximab)c
− 1.52c 84.8 (PBO/
infliximab)c
83.8c
IMPACT 2 (infliximab
vs placebo) [20]
SvdH 24 and 54 0.82 − 0.70 78.0 90.0
GO-REVEAL
(golimumab vs
placebo) [21]
SvdH 24 and 52 0.27 − 0.09 62.7b 77.7b
GO-VIBRANT
(golimumab vs
placebo) [22]
SvdH 24 2.0 − 0.4 43.0b 71.7b
RAPID-PsA
(certolizumab
pegol) [23, 24]
SvdH 12 and 24 0.28 0.06 (200 mg Q2W +
400mg Q4W)
80.1 93.5 (200mg Q2W); 90.4
(400mg Q4W)
PSUMMIT-1 and -2
(ustekinumab vs
placebo) [25]
SvdH 24 and 52 1.0 0.4 59.8b 66.5b
FUTURE 1
(secukinumab
vs placebo) [26]
SvdH 16 or 24 and
52
0.57 0.08 (pooled
secukinumab group)
75.7 82.3 (IV→ 150mg); 92.3
(IV→ 75 mg)
FUTURE 5
(secukinumab
vs placebo) [27]
SvdH 24 0.5 0.08 (300 mg + LD); 0.17
(150 mg + LD); − 0.09
(150 mg − LD)
73.6 88.0.(300 mg + LD); 79.8
(150mg + LD); 83.8
(150mg − LD)
SPIRIT-P1 (ixekizumab
vs placebo vs
adalimumab) [28]
SvdH 24 and 52 0.27 (PBO/
IXEQ4W)d; 0.41
(PBO/IXEQ2W)d
0.54 (IXEQ4W/IXEQ4W)d;
0.09 (IXEQ2W/IXEQ2W)d;
0.32 (ADA/IXEQ4W)d;
− 0.03 (ADA/IXEQ2W)d
94.1 (PBO/
IXEQ4W)d;
65.7 (PBO/IXEQ2W)d
88.9 (IXEQ4W/IXEQ4W)d; 90.4
(IXEQ2W/IXEQ2W)d; 87.5 (ADA/
IXEQ4W)d; 91.4 (ADA/IXEQ2W)d
ASTRAEA (abatacept
vs placebo) [29]
SvdH 24 and 52 0.35 0.30 32.7b 42.7b
OPAL Broaden
(tofacitinib vs
adalimumab vs
placebo) [30]
SvdH 12months Not reported by treatment arm.
Range of change from baseline,
− 0.07 to 0.09a
95.8 (PBO/TOFA 5mg)a;
91.1 (PBO/TOFA 10mg)a
95.9 (TOFA 5 mg)a; 94.9
(TOFA 10mg)a; 97.9 (ADA)a
SEAM-PsA
(methotrexate vs
etanercept vs
combination) [31]
SvdH 24 and 48 – 0.08 (MTX)e; − 0.04
(ETN)e; − 0.01
(MTX + ETN)e
– 89.4 (MTX)b,e; 94.7 (ETN)b,e; 94.7
(MTX + ETN)b,e
ADA adalimumab, ETN etanercept, IXE ixekizumab, LD loading dose, MTX methotrexate, PBO placebo, PsA psoriatic arthritis, Q2W every 2 weeks, Q4W every 4
weeks, SvdH modified Sharp-van der Heijde score for PsA, TOFA tofacitinib
aMean change from baseline at 12 months
bNo progression was defined as a mean change of ≤ 0 from baseline
cMean change from baseline at week 50
dMean change from baseline at week 52
eMean change from baseline at week 48
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detectable change. The SvdH method was the most reli-
able and sensitive to change but required a longer time
to perform. The Steinbrocker method was the most feas-
ible (i.e., took the least time to perform) but was not as
sensitive as the SvdH or modified Sharp score. The au-
thors concluded that the SvdH scoring method for PsA
was the best tool for use in randomized controlled trials.
Although a case study has shown that scoring methods
can detect changes in radiographic damage over time in
patients with PsA [35], Tillet and colleagues found that
none of the methods currently available provide an ad-
equate level of feasibility and sensitivity for application
in large, longitudinal studies [33]. The importance of
meeting this need is highlighted in the European League
Against Rheumatism (EULAR) research agenda, which
seeks to define the optimal use of radiographic scores
for monitoring structural damage progression in longitu-
dinal studies of PsA [11].
Assessment of structural damage progression in
clinical research
Structural damage as an outcome measure in clinical
trials
The utility of radiographic assessment of structural dam-
age as an outcome in PsA is illustrated by several phase
3 clinical trials of biologic agents used to treat PsA
(Table 2) [15, 17, 19–32, 34, 36]. The first studies of the
biologic agents etanercept [15] and adalimumab [17] in
PsA used a modified Sharp score for PsA to assess the
effect of therapy on structural damage. In the study
evaluating etanercept vs placebo, the primary radio-
graphic endpoint was the annualized rate of change in
the modified Sharp score for PsA at 6 and 12months
[15]. At 12 months, etanercept led to inhibition of radio-
graphic progression in the hands and wrists compared
with worsening in the placebo group (P = .0001); annu-
alized changes in the erosion score and joint space nar-
rowing scores were also significantly different in the two
groups. In the ADEPT study of adalimumab vs placebo,
inhibition of structural damage, as measured by the
Sharp method for PsA at week 24, was a primary efficacy
endpoint [17]. At week 24, active treatment demon-
strated significant inhibition of structural damage pro-
gression compared with placebo (P < .001). Significant
differences were also observed in erosion and joint space
narrowing scores.
Since then, other trials of biologics in PsA have used
the SvdH scoring system (Table 2). The IMPACT stud-
ies were some of the first studies to use the SvdH
method to assess structural damage in patients with PsA
being treated with a biologic agent (infliximab) [19, 20].
The primary outcome was mean progression of struc-
tural damage as demonstrated by the mean changes
from baseline in the total SvdH score, with positive
changes from baseline indicating progression of struc-
tural damage. The studies showed that the SvdH scoring
method was appropriate for use in PsA; however, the
usefulness of scoring features characteristic of PsA (e.g.,
hand DIP joints, pencil-in-cup changes, gross osteolysis)
was limited, as had been observed previously when using
the Sharp method in PsA [15, 17]. This was mainly due
to the low progression rate of these features over 6 to
12months. Importantly, the IMPACT studies showed
that biologic treatments were able to inhibit radiographic
progression as early as 6 months, and therefore assess-
ment of structural damage in clinical trials can be per-
formed after 6 months as opposed to waiting 1 to 2 years
to assess damage. These studies also suggested that for
ethical reasons, patients in clinical trials should not be
offered placebo for long periods of time but should be
allowed to receive active treatment after a 6-month
period.
In line with these findings, the GO-REVEAL [21] and
GO-VIBRANT [22] studies of golimumab showed that
24 weeks of follow-up are sufficient for radiographic
damage as an outcome. In these studies, the change
from baseline in the SvdH scoring method for PsA of
the hands and feet at week 24 was one of the two
coprimary endpoints (Table 2). Scores for PsA-specific
radiologic damage (e.g., DIPs, pencil-in-cup, and gross
osteolysis deformities) were also included. As seen in the
IMPACT studies, patients who originally received pla-
cebo and later crossed over to receive active treatment
had more structural damage after 1 year than did pa-
tients who originally received active treatment, suggest-
ing a benefit associated with earlier treatment.
As new targeted therapies for PsA have been devel-
oped, inhibiting radiographic progression has become
essential for demonstrating efficacy and disease-
modifying activity. For instance, the phase 3 studies
PSUMMIT-1 and PSUMMIT-2 of the anti–interleukin
(IL) 12/IL-23 antibody ustekinumab assessed changes
from baseline in radiographic progression at week 24
using the SvdH method for PsA (Table 2) [25]. Findings
from this study showed that inhibiting targets other than
tumor necrosis factor (i.e., IL-12 and IL-23) could also
lead to improvements in PsA and inhibition of radio-
graphic progression. In the FUTURE studies of secuki-
numab (an anti–IL-17 inhibitor), inhibition of
radiographic progression was a key secondary endpoint
[26, 27, 34]. Patients treated with secukinumab had sig-
nificantly less radiographic progression, defined as the
change from baseline in SvdH score at week 24. Inhib-
ition of radiographic progression was sustained up to 2
years for both erosion and joint space narrowing [26,
37]. These studies demonstrated that targeting IL-17A
was another therapeutic option for patients with PsA.
Similar assessments of radiographic progression were
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conducted in the SPIRIT-P1 study of ixekizumab, an-
other IL-17 inhibitor [28, 32], and in studies of the Janus
(JAK) inhibitor tofacitinib [30] and the T cell modulator
abatacept [29] (Table 2).
The impact of methotrexate on radiographic outcomes
has also been assessed. The phase 3 randomized study
SEAM-PsA, which examined the efficacy of methotrex-
ate and etanercept monotherapies vs methotrexate in
combination with etanercept [31, 36] (Table 2), found
that concomitant methotrexate did not lead to signifi-
cant changes in radiographic outcomes, consistent with
previous observations [15, 26]. However, in studies of
golimumab [21] and infliximab [20], treatment group
differences were larger in patients receiving concomitant
methotrexate.
Limitations and considerations in the analysis of
radiographic progression in clinical trials
Given that it is based on subjective interpretation of
radiographic changes, the assessment of radiographic
progression is subject to possible measurement error
and variability. In general, the presence of radiographic
damage in clinical trials is preferably assessed by 2 or 3
central readers to ensure reliable information [38]. Add-
itionally, a mean change of ≤ 0.5 in total score (vs 0) is
preferred when the mean of two readers is used to deter-
mine the absence of radiographic progression.
A main challenge in assessing radiographic progres-
sion is detecting a treatment effect [39, 40]. Ethical con-
siderations in clinical trials limit the duration of placebo
treatment, impacting the ability to detect radiographic
progression in this group. Additionally, patients random-
ized to placebo are allowed to switch to active treatment
due to lack of efficacy or to discontinue the study before
radiographic progression is assessed or discernable.
These low rates of radiographic progression in the con-
trol group and incomplete radiographic data may impact
the statistical power of these trials to detect a treatment
effect [39].
Another important challenge is mitigating the impact
of missing radiographic data. Linear extrapolation and
interpolation is a widely used approach and requires
radiographic data from ≥ 2 time points [23, 27]. Linear
mixed-effects models, which account for important co-
factors such as previous treatment and baseline values,
are another approach that can maximize the statistical
power of clinical trials and mitigate the effect of missing
data. These methodologies have been used in various
studies. For example, in the IMPACT-2 study, missing
data were imputed using linear extrapolation or the me-
dian of the change in total scores based on all patients
within the same methotrexate stratification (i.e., a me-
dian of 0) [20]. In the GO-REVEAL study, linear ex-
trapolation was used, and if data were insufficient for
linear extrapolation, the median change in total SvdH
score was used to replace missing data [21]. However,
imputation of median scores is no longer applied. In the
FUTURE5 study, radiographic data were analyzed by a
linear mixed-effects model that excluded data after es-
cape for patients treated with placebo who received es-
cape therapy at week 16. The model assumed
approximately linear progression over time and esti-
mated a difference in rates of progression over 24 weeks
to compare treatment groups [41]. However, it is im-
portant to note that imputation methodologies may sig-
nificantly influence interpretation of radiographic
outcomes, as seen in the RAPID-PsA phase 3 study of
certolizumab pegol, where (incorrect) imputation meth-
odologies resulted in a high degree of progression in all
arms [23]. In this study, not imputing missing data for
patients with ≤ 1 radiograph or 2 radiographs < 8 weeks
apart and linear extrapolation in patients with two radio-
graphs ≥ 8 weeks apart were found to be the most appro-
priate methods for the primary analysis.
In addition to imputation methodologies, enriching for
patients who are at high risk of radiographic progression
may increase the power of a study to detect treatment
effects [39]. This could be achieved by increasing the
number of patients who present with predictive factors
for radiographic progression or by indirectly enriching
the data through post hoc analyses. Although predictive
factors for radiographic progression in PsA are limited,
systemic inflammation as indicated by elevated baseline
C-reactive protein has been shown to be a strong inde-
pendent predictor of radiographic progression and may
serve as a way of enriching for high-risk patients [42,
43]. Similarly, the existence of radiographic damage is
another predictive factor. Patients with damage are more
prone to develop more damage, especially in the pres-
ence of an elevated C-reactive protein.
Another limitation of clinical trials that assess struc-
tural damage in PsA is that they tend to focus on radio-
graphic progression in peripheral joints only. For
instance, structural changes associated with enthesitis,
including anabolic bone formation, are not generally
assessed, and no systematic method of measurement is
currently available [12]. Similarly, progression in the
axial skeleton is not commonly measured. Different
scoring methods for assessment of axial involvement are
available [44]; however, they have not been used in large
clinical trials of PsA so far. A further limitation is that
minimum clinically important differences for radio-
graphic scores have not yet been established.
Future areas of research
Scoring methods for other imaging techniques (i.e.,
micro-computed tomography scan, ultrasound, MRI)
should be developed, validated, and further tested for
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their propensity to assess structural damage in PsA [11].
So far, only MRI has been used and is scored using the
Psoriatic Arthritis Magnetic Resonance Image score
(PsAMRIS) [45, 46]. PsAMRIS is a semiquantitative
scoring system that has been developed for PsA by the
international MRI in arthritis group of OMERACT
(Outcome Measures in Rheumatology) [45, 46] and is
the most validated system available for the evaluation of
inflammatory and structural changes in the hands of pa-
tients with PsA [45]. PsAMRIS has been used in a few
small trials in which a significant improvement in in-
flammatory parameters was demonstrated following
treatment with a biologic agent; however, bone damage
parameters, such as bone proliferation and erosion,
showed little change over time [45]. New developments
in MRI approaches, such as dynamic contrast-enhanced
MRI and digital automated analysis, may improve MRI
techniques [47].
Additionally, further refinement of radiographic scor-
ing methods specific for PsA merits investigation. For
example, radiographic scoring methods could be im-
proved by accounting for the progression of new bone
growth, which is characteristic of PsA. Another area of
development could be the use of artificial intelligence to
assess structural damage on radiographs.
Conclusions
Structural damage in patients with PsA is associated
with decreased quality of life and physical function and
increased risk of death. Therefore, inhibition of struc-
tural damage progression is a key aspect of treatment
and a characteristic of disease-modifying therapies in
PsA. This has led to radiographic progression becoming
an important outcome measure in clinical trials that is
needed to identify effective therapies for patients with
PsA. As sustained inhibition of radiographic progression
becomes an important goal in the management of the
disease, further research will be necessary to determine
the best way of assessing radiographic progression long
term.
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